...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Graffinity Enters into Drug Discovery Collaboration with Shionogi

| Print |
Wednesday, 30 March 2011 07:00 (UTC + 2)

Graffinity_logo

Heidelberg, Germany, March 30, 2011 / b3c newswire / - Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies, announced today that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co., Ltd. Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target.

 

Financial details of the transaction were not disclosed.

 

Mathias Woker, Chief Business Officer of Graffinity, remarked, ”We are pleased that Shionogi has chosen to collaborate with us to apply our fragment based screening platform to one of Shionogi’s high priority discovery programs. This marks our first collaboration with a leading Japanese pharmaceutical company. Our proprietary assay/label-free SPR primary screen of 24,000 fragments and 87,000 leadlike molecules is often crucial in addressing drug targets that are difficult to screen with other technologies.”

 

 

About Graffinity Pharmaceuticals GmbH - www.graffinity.com
Heidelberg, Germany based Graffinity Pharmaceuticals, a member of the NovAliX group of companies, is a leader in the field of small molecule fragment-based drug discovery. Graffinity’s fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR-imaging. The company’s rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 24,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. Graffinity’s unique fragment based discovery platform was invented in 1998, and has been in routine industrial use since 2002 in screening more than 90 drug targets.

 


Media Contact Graffinity for Europe
Dr. Kristina Schmidt
CEO
Graffinity Pharmaceuticals GmbH
Tel.  +49 6221 6510-112
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 
Graffinity Media Contact for the Americas and Asia

Mathias Woker
CBO
Graffinity Pharmaceuticals GmbH
Tel.  +1 (401) 301-1086
This e-mail address is being protected from spambots. You need JavaScript enabled to view it